Placebo to match DNTH103, Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, DNTH103, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, c
DNTH103-MG-201
Phase 2 small_molecule active
Quick answer
Placebo to match DNTH103, Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, DNTH103, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, c for Generalized Myasthenia Gravis is a Phase 2 program (small_molecule) at Dianthus Therapeutics, Inc. /DE/ with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Dianthus Therapeutics, Inc. /DE/
- Indication
- Generalized Myasthenia Gravis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active